| Nov 13 |
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
|
| Nov 7 |
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...
|
| Nov 7 |
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
|
| Nov 6 |
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
MaxCyte GAAP EPS of -$0.11 beats by $0.01, revenue of $8.2M beats by $0.84M
|
| Nov 6 |
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
|
| Oct 31 |
MaxCyte to Participate in Two Upcoming Investor Conferences
|
| Oct 30 |
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company
|
| Oct 16 |
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
| Oct 15 |
MaxCyte Appoints Cynthia Collins to its Board of Directors
|
